10-1-2021

TCT-100 Real-World Experience and Outcomes of Protected Versus Unprotected Left Main Percutaneous Coronary Intervention: Insights From the VA CART Program

Y Hussain

Pedro Engel Gonzalez

Henry Ford Health, pengel1@hfhs.org

R Khera

S Banerjee

A Hebbe

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/cardiology_mtgabstracts

Recommended Citation

This Conference Proceeding is brought to you for free and open access by the Cardiology/Cardiovascular Research at Henry Ford Health Scholarly Commons. It has been accepted for inclusion in Cardiology Meeting Abstracts by an authorized administrator of Henry Ford Health Scholarly Commons.
Authors

This conference proceeding is available at Henry Ford Health Scholarly Commons:
https://scholarlycommons.henryford.com/cardiology_mtgabstracts/313
BACKGROUND The optimal duration of dual antiplatelet therapy (DAPT) in patients with high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI) varies based on individual clinical and lesion characteristics. It is unknown whether patients with HBR and bifurcation lesions can be safely treated with an abbreviated DAPT. In this analysis, we examined ischemic and bleeding outcomes at 1 year in patients with and without bifurcations who underwent PCI in the Onyx ONE Clear study.

METHODS Patients meeting at least 1 HBR criterion undergoing PCI with Resolute Onyx zotarolimus-eluting stents (Medtronic) were enrolled. DAPT was required for the first month post-procedure and single antiplatelet therapy (SAPT) thereafter. In this analysis, 1-year outcomes were assessed in patients with and without treated index procedure bifurcation lesions as reported by the study investigators.

RESULTS Of 1,506 patients in the Onyx ONE Clear study, 218 (14.5%) had treated index procedure bifurcation lesions. Among these, 89% were treated with a provisional stenting technique and 11% with a 2-stent technique. Patients with versus without bifurcation lesions had similar baseline clinical characteristics; however, procedure time was greater for patients with bifurcations (49.2 ± 3.4 vs 40.6 ± 28.7 minutes, P < 0.001), as was total stent length (45.3 ± 3.5 vs 35.5 ± 24.9 mm, P < 0.001). SAPT use after 1 month was 97% for patients both with and without bifurcations. The primary study endpoint of composite cardiac death or myocardial infarction at 1 year was nonsignificantly different but was numerically higher for patients with versus without bifurcations (9.8% vs 6.5%, P = 0.08), as were the rates of other ischemic events (Table 1). Conversely, major bleeding events (Bleeding Academic Research Consortium [BARC] 3-5) were less prevalent for patients with bifurcations, in part relating to differences in rates of oral anticoagulation between groups.

CONCLUSION In the Onyx ONE Clear study, patients with HBR and bifurcations treated with Resolute Onyx zotarolimus-eluting stents and only 1-month DAPT tended to have nonsignificantly different but numerically slightly higher ischemic event rates and less major bleeding compared with patients without bifurcation lesions. Further studies are required to determine the optimal DAPT duration following PCI for HBR patients with coronary bifurcation lesions.

CATEGORIES: Stents: Drug-Eluting

**TCT-100**

Real-World Experience and Outcomes of Protected Versus Unprotected Left Main Percutaneous Coronary Intervention: Insights From the VA CART Program

Yasin Hussain,1 Pedro Engel Gonzalez,2 Rohan Khera,1 Subhash Banerjee,4 Annika Hebbe,1 Mary Plomondon,1 Stephen Waldo,3 Steven Pfau,7 Jeptha Curtis,2 Samit Shah10 Yale School of Medicine, New Haven, Connecticut, USA;2 Henry Ford Hospital, Detroit, Michigan, USA;3 Yale School of Medicine, New Haven, Connecticut, USA;4 UT Southwestern and VA North Texas, Dallas, Texas, USA;5 VA Eastern Colorado HealthCare, Aurora, Colorado, USA;6 VA Eastern Colorado Healthcare, Aurora, Colorado, USA;7 Veterans Administration/University of Colorado, Denver, Colorado, USA;8 Yale University, New Haven, Connecticut, USA;9 Yale University, New Haven, Connecticut, USA;10 Yale New Haven Hospital, Fairfield, Connecticut, USA

BACKGROUND Outcomes of protected left main (PLM) and unprotected left main (ULM) percutaneous coronary intervention (PCI) are not well defined in contemporary U.S. practice. Previous studies of real-world data have shown worse in-hospital outcomes of ULM PCI compared with randomized trial data. We used a large national registry to characterize real-world practice and outcomes of left main PCI.

METHODS Data were collected from the Veteran Affairs (VA) Clinical Assessment Reporting and Tracking (CART) Program for patients undergoing left main PCI between 2009 and 2019. PLM PCI was defined by the presence of at least 1 functioning bypass graft, and ULM PCI was defined as patients with no bypass grafting. Temporal trends, patient, and procedure characteristics, anatomic complexity, and clinical complexity were assessed. A 1-to-1 propensity-matched analysis was performed using common comorbidities and clinical variables. One-year outcome analyses were conducted for major adverse cardiovascular events (MACE), all-cause mortality, rehospitalization for myocardial infarction (MI) and revascularization.

RESULTS Of 4,351 patients undergoing left main PCI, 2,800 were PLM PCI and 1,551 were ULM PCI, of which 1,335 PLM and ULM PCI were included in the propensity matched cohort. Patients undergoing ULM PCI were older, more likely to present with acute coronary syndrome (ACS) and had a higher clinical complexity. In the propensity-matched cohort, there was no difference in age, rate of ACS presentation, burden of comorbidities, or left ventricular ejection fraction. There were no differences in in-hospital adverse events between the 2 groups. At 12 months, MACE occurred more frequently with ULM PCI compared with PLM PCI (25% [334] vs 20% [270]; P = 0.004), and all-cause mortality was also higher (18% [239] vs 14% [185]; P = 0.005). There was no difference in rehospitalization for MI, stroke, or revascularization at 12 months.

CONCLUSION In the VA Healthcare System, patients undergoing ULM PCI were older and more clinically complex than those undergoing PLM PCI. In the propensity-matched cohort, patients undergoing ULM PCI had better 12 outcomes than those undergoing ULM PCI, but there was a high rate of mortality and MACE at 1 year in both groups, despite a relatively low rate of MI or revascularization.

CATEGORIES CORONARY: Complex and Higher Risk Procedures for Indicated Patients (CHIP)

**TCT-101**

Long-Term Outcomes Following Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Treating In-Stent Restenosis in Unprotected Left Main Coronary Artery: Multicenter LM-DRAGON Registry

Wojciech Waniha,1 Jacek Bil,2 Michalina Kołodziejczak,3 Adam Kowalowka,1 Damian Hudziak,1 Radosław Gocłowski,1 Mariusz Kowalewski,1 Rafał Januszewski,1 Tomasz Figatowski,9 Marek Milewski,10 Brunon Tomaszewicz,11 Piotr Kubler,12 Piotr Desperak,13 Łukasz Kuzma,14 Krzysztof Milewski,14 Bartłomiej Gora,15 Andrzej Los,16 Jan Kulczycki,17 Adrian Wlodarczak,18 Marek Grygier,19 Maciej Lesiak,20 Paweł Kieczyński,21 Radosław Litwinowicz,9 Andrea Borin,23 Grzegorz Smolka,1 Krzysztof Reczuch,23 Marcin Gruchała,24 Robert Gil,25 Miłosz Jaguszewski,26 Krzysztof Bartus,28 Piotr Suwalski,27 Sławomir Dobrzyński,29 Bartłomiej Dudek,28 Stanisław Bartus,29 Mariusz Gasiór,1 Jacek Legutko,12 Argerz Ochala,26 Alexandra Lansky,27 Marek Deja,23 Elvin Keski,26 Wojciech Wojakowski10